Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
BMC Musculoskelet Disord. 2022 Apr 2;23(1):313. doi: 10.1186/s12891-022-05236-6.
BACKGROUND: Osteochondral lesions of the talus (OLT) are common after ankle trauma. Studies have shown that bioactive substances, such as hyaluronic acid (HA), alone, or in combination, with surgical treatment could improve cartilage regeneration and repair, but the effect of HA on patient reported outcomes is unclear. METHODS: Literature searches were performed across four databases (PubMed, SPORTDiscus, Scopus, and The Cochrane Library) for randomized controlled trials in which at least one treatment arm involved use of HA as an adjunct to microfracture to treat patients with OLT. Primary outcomes included the American Orthopaedic Foot and Ankle Society scores (AOFAS), and the Visual Analog Scale (VAS) for pain. The level of evidence and methodological quality were evaluated using the Modified Coleman Methodology Score (MCMS). RESULTS: Three randomized studies were eligible for review with a total of 132 patients (35, 40, 57 patients, respectively) and follow-up ranged from 10.5 to 25 months. Utilization of HA at the time of microfracture resulted in greater improvement in AOFAS scores compared to microfracture alone. The pooled effect size was moderate (Standardized Mean Difference [SMD] 0.45, 95% Confidence Interval [CI] 0.06, 0.84; P = .02) and between-study heterogeneity was low (I-squared = 0%). Utilization of HA during microfracture also led to greater improvement in VAS-pain scores compared to microfracture alone. The pooled effect size was very large (SMD -3.86, 95% CI -4.75, - 2.97; P < .001) and heterogeneity was moderate (I-squared = 69%). CONCLUSION: Hyaluronic acid injection as an adjunct to arthroscopic MF in OLT provides clinically important improvements in function and pain at short-term follow-up compared to MF alone. Future longer-term follow-up studies are warranted to investigate the durability of MF with HA for treatment of OLT.
背景:距骨骨软骨损伤(OLT)是踝关节创伤后的常见并发症。研究表明,生物活性物质(如透明质酸[HA])单独或联合手术治疗可改善软骨再生和修复,但 HA 对患者报告结果的影响尚不清楚。
方法:在四个数据库(PubMed、SPORTDiscus、Scopus 和 The Cochrane Library)中进行文献检索,纳入至少有一个治疗组使用 HA 作为微骨折术的辅助治疗 OLT 患者的随机对照试验。主要结局包括美国矫形足踝协会评分(AOFAS)和疼痛视觉模拟量表(VAS)。使用改良 Coleman 方法学评分(MCMS)评估证据水平和方法学质量。
结果:有 3 项随机研究符合纳入标准,共纳入 132 例患者(分别为 35、40、57 例),随访时间为 10.5 至 25 个月。与单纯微骨折术相比,微骨折术中使用 HA 可显著提高 AOFAS 评分。合并效应量为中等(标准化均数差 [SMD] 0.45,95%置信区间 [CI] 0.06,0.84;P=.02),异质性低(I-squared=0%)。微骨折术中使用 HA 也可显著降低 VAS 疼痛评分。合并效应量为非常大(SMD -3.86,95% CI -4.75,-2.97;P<.001),异质性中等(I-squared=69%)。
结论:与单纯微骨折术相比,OLT 关节镜下微骨折术中联合注射 HA 可在短期随访时提供更显著的功能和疼痛改善。需要进一步进行长期随访研究,以评估 HA 联合微骨折术治疗 OLT 的耐久性。
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2018-9-19
Cochrane Database Syst Rev. 2021-9-14
Cochrane Database Syst Rev. 2018-6-22
Cochrane Database Syst Rev. 2018-3-1
Cochrane Database Syst Rev. 2024-1-8
Cochrane Database Syst Rev. 2021-10-12
Cochrane Database Syst Rev. 2025-1-29
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2025-7-15
Front Med (Lausanne). 2024-11-20
Orthop J Sports Med. 2019-10-22
Acta Orthop Traumatol Turc. 2019-9